Okyo Pharma (OKYO)

Okyo Pharma Limited

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:OKYO

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
30/10/2024	11:00	UK Regulatory	OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference	LSE:OKYO	Okyo Pharma Limited
23/10/2024	11:00	UK Regulatory	OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
16/10/2024	11:00	UK Regulatory	OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
10/09/2024	11:00	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
05/09/2024	11:00	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
27/08/2024	11:00	UK Regulatory	OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease	LSE:OKYO	Okyo Pharma Limited
23/08/2024	13:00	UK Regulatory	OKYO Pharma CEO Interview to Air on Bloomberg TV	LSE:OKYO	Okyo Pharma Limited
23/08/2024	11:00	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
21/08/2024	11:00	UK Regulatory	OKYO Pharma Announces Chairman Acquires Shares	LSE:OKYO	Okyo Pharma Limited
15/08/2024	16:13	UK Regulatory	OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference	LSE:OKYO	Okyo Pharma Limited
06/08/2024	11:00	UK Regulatory	OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use	LSE:OKYO	Okyo Pharma Limited
11/07/2024	11:00	UK Regulatory	OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101	LSE:OKYO	Okyo Pharma Limited
10/07/2024	11:00	UK Regulatory	OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease	LSE:OKYO	Okyo Pharma Limited
08/05/2024	11:00	UK Regulatory	OKYO Pharma Announces Participation in May 2024 Investor Conferences	LSE:OKYO	Okyo Pharma Limited
30/04/2024	11:00	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	LSE:OKYO	Okyo Pharma Limited
08/04/2024	23:00	UK Regulatory	OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	LSE:OKYO	Okyo Pharma Limited
02/04/2024	11:00	UK Regulatory	OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	LSE:OKYO	Okyo Pharma Limited
22/03/2024	11:00	UK Regulatory	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	LSE:OKYO	Okyo Pharma Limited
21/03/2024	11:00	UK Regulatory	OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	LSE:OKYO	Okyo Pharma Limited
20/03/2024	11:00	UK Regulatory	OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	LSE:OKYO	Okyo Pharma Limited
09/02/2024	12:36	InvestorsHub NewsWire	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
09/02/2024	12:00	UK Regulatory	OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	LSE:OKYO	Okyo Pharma Limited
31/01/2024	12:00	UK Regulatory	OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	LSE:OKYO	Okyo Pharma Limited
22/05/2023	07:15	UK Regulatory	OKYO Pharma Limited London Stock Exchange Delisting	LSE:OKYO	Okyo Pharma Limited
22/05/2023	07:00	UK Regulatory	London Stock Exchange Notice Cancellation - OKYO PHARMA LIMITED	LSE:OKYO	Okyo Pharma Limited
19/05/2023	10:22	Alliance News	IN BRIEF: Okyo Pharma to move shares to New York with London delisting	LSE:OKYO	Okyo Pharma Limited
19/05/2023	07:00	RNS Non-Regulatory	OKYO Pharma Limited ADS Program collapse	LSE:OKYO	Okyo Pharma Limited
15/05/2023	06:00	UK Regulatory	OKYO Pharma Limited Change of Record Time and Last Day of Dealings	LSE:OKYO	Okyo Pharma Limited
11/05/2023	13:27	Alliance News	IN BRIEF: Okyo Pharma delays delisting from London trading to May 22	LSE:OKYO	Okyo Pharma Limited
11/05/2023	11:00	RNS Non-Regulatory	OKYO Pharma Limited Webull Corporate Communications Service Platform	LSE:OKYO	Okyo Pharma Limited